Font size: Normal | Large | X-Large
 

Clinical Trials

Treatment of retinal diseases is a rapidly changing field of medicine with new techniques and procedures being developed every year. Southwest Retina Specialists has been involved with research over the last six years for a variety of retina conditions, including Diabetic Macular Edema, Vitreous Hemorrhage with surgical intervention, and Age-Related Macular Degeneration.

While clinical trials are always voluntary, to qualify a patient would go through a screening process to determine eligibility that varies from study to study.

Please contact our study coordinator, Kasey Dalrymple, at 806-351-1870 (ext. 1113) if you are interested in being screened or want more information on a clinical trial being conducted.

You can learn more about each trial and how to participate in a clinical trial at:
http://www.ClinicalTrials.gov
http://www.fda.gov

Current Studies Open for Enrollment:

GLEAM
Diabetic Macular Edema (Actively Recruiting)

Kodiak Sciences
This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with treatment-naïve DME.

  • ClinicalTrials.gov Identifier: NCT04611152
  • Sponsor: Kodiak Sciences Inc
  • Site: Southwest Retina Specialist, Amarillo, TX.

 

GLOW
Moderate Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR) (Actively Recruiting)

Kodiak Sciences
This is a Phase 3, prospective, randomized, double-masked, sham-controlled, two-arm, multicenter study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

  • ClinicalTrials.gov Identifier: NCT05066230
  • Sponsor: Kodiak Sciences Inc
  • Site: Southwest Retina Specialist, Amarillo, TX.

 

DAYLIGHT
Neovascular (Wet) Age Related Macular Degeneration (Actively Recruiting)

Kodiak Sciences
This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with visual impairment due to treatment-naïve neovascular (wet) age-related macular degeneration (wAMD)

  • ClinicalTrials.gov Identifier: NCT04964089
  • Sponsor: Kodiak Sciences Inc
  • Site: Southwest Retina Specialist, Amarillo, TX.

DRY MACULAR DEGENERATION (Active Investigation/Closed Enrollment)

Apellis 303 Derby
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

  • ClinicalTrials.gov Identifier: NCT03525600
  • Sponsor: Apellis Pharmaceuticals, Inc.
  • Site: Southwest Retina Specialist, Amarillo, TX